Biotheus Inc.

Although 2024 got off to a promising start with a busy first quarter, the fourth quarter marked the third consecutive quarter of declining biopharma merger-and-acquisition valuation. Evaluate reported

BioNTech’s close to $1bn acquisition of Biotheus announced earlier this month marked another big M&A deal between a Chinese biotech and a foreign firm following AstraZeneca’s roughly $1.2bn buyou

BioNTech is striving to be a major player in immuno-oncology as it further develops its pipeline of bispecific antibodies, CAR-T cell therapies and antibody-drug conjugates (ADC), with one of the bisp

After a year as licensee of Biotheus’s PD-L1 and VEGF-A-targeting bispecific BNT327, BioNTech has decided to buy the Chinese company outright, spending $800m upfront to do so. Though Biotheus has othe